Ask AI

InterACT Oncology Team Training: Integrating ADCs Into Patient-Centered Management of HER2-Negative/Ultralow/Low MBC—Enhancing the Patient–Provider Therapeutic Connection

Enhance your understanding of ADCs used to treat HER2-negative/ultralow/low metastatic breast cancer (MBC) to better manage therapy-related toxicities and optimize patient outcomes through certified Medical Minute modules, a podcast, expert-authored ClinicalThought commentary, and downloadable slides.

Share

Program Content

Events

Activities

ADCs for MBC
ADCs for HER2-Negative/Ultralow/Low MBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC In partnership with Smart Patients, Inc.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Smart Patients, Inc.

ProCE Banner